| 2026-08-03 | Deck | Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale |
| 2026-08-03 | Press release | PDF Version |
| 2026-08-03 | Press release | Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with |
| 2026-08-03 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-03 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-03 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-22 | 8-K | Form 8-K, Item 2.02 results |
| 2026-06-29 | Press release | Supernus to Participate in Annual Piper Sandler Healthcare Conference |
| 2026-06-18 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-17 | Press release | Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022 |
| 2026-06-16 | Press release | Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 |
| 2026-06-16 | Press release | Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 |
| 2026-06-16 | Press release | Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023 |
| 2026-06-16 | Press release | Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022 |
| 2026-06-16 | Press release | Supernus to Participate in Annual Cowen Health Care Conference March 2, 2022 |
| 2026-06-16 | Press release | Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call February 23, 2021 |
| 2026-06-16 | Press release | Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference |
| 2026-06-16 | Press release | Supernus to Host Third Quarter 2020 Financial Results Conference Call October 27, 2020 |
| 2026-06-16 | Press release | Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference September 9, 2020 |
| 2026-05-20 | 8-K | Form 8-K, Item 2.03 |
| 2026-05-11 | Deck | Supernus Pharmaceuticals Corporate Overview |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-30 | Proxy | Stockholder Meeting Notice |
| 2026-04-30 | Proxy | NOTICE OF ANNUAL MEETING OF STOCKHOLDERS |
| 2026-04-30 | Proxy | Definitive proxy statement |
| 2026-04-22 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-07 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-02 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-26 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-24 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-24 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-28 | 8-K | Form 8-K, Item 9.01 |
| 2025-11-06 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-11-04 | Press release | Supernus Announces Third Quarter 2025 Financial Results |
| 2025-11-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-21 | Press release | Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 |
| 2025-10-21 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-16 | 8-K | Form 8-K/A, Item 9.01 |